Compare Lupin with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs DR. REDDYS LAB - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN DR. REDDYS LAB LUPIN/
DR. REDDYS LAB
 
P/E (TTM) x -299.2 53.3 - View Chart
P/BV x 3.9 5.3 72.9% View Chart
Dividend Yield % 0.6 0.5 111.9%  

Financials

 LUPIN   DR. REDDYS LAB
EQUITY SHARE DATA
    LUPIN
Mar-20
DR. REDDYS LAB
Mar-20
LUPIN/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8823,363 26.2%   
Low Rs5052,352 21.5%   
Sales per share (Unadj.) Rs339.41,054.2 32.2%  
Earnings per share (Unadj.) Rs-5.9121.9 -4.9%  
Cash flow per share (Unadj.) Rs15.5190.2 8.1%  
Dividends per share (Unadj.) Rs6.0025.00 24.0%  
Dividend yield (eoy) %0.90.9 98.9%  
Book value per share (Unadj.) Rs276.7938.7 29.5%  
Shares outstanding (eoy) m453.00166.17 272.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.7 75.4%   
Avg P/E ratio x-116.623.4 -497.7%  
P/CF ratio (eoy) x44.815.0 298.4%  
Price / Book Value ratio x2.53.0 82.3%  
Dividend payout %-100.920.5 -492.1%   
Avg Mkt Cap Rs m314,201474,831 66.2%   
No. of employees `00018.321.7 84.5%   
Total wages/salary Rs m29,86833,802 88.4%   
Avg. sales/employee Rs Th8,400.68,091.0 103.8%   
Avg. wages/employee Rs Th1,632.01,561.3 104.5%   
Avg. net profit/employee Rs Th-147.2935.8 -15.7%   
INCOME DATA
Net Sales Rs m153,748175,170 87.8%  
Other income Rs m4,8386,206 78.0%   
Total revenues Rs m158,585181,376 87.4%   
Gross profit Rs m24,84924,421 101.8%  
Depreciation Rs m9,70211,348 85.5%   
Interest Rs m3,630983 369.3%   
Profit before tax Rs m16,35518,296 89.4%   
Minority Interest Rs m40-   
Prior Period Items Rs m39561 7.0%   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,571-1,403 -824.7%   
Profit after tax Rs m-2,69420,260 -13.3%  
Gross profit margin %16.213.9 115.9%  
Effective tax rate %70.8-7.7 -922.6%   
Net profit margin %-1.811.6 -15.1%  
BALANCE SHEET DATA
Current assets Rs m154,132125,991 122.3%   
Current liabilities Rs m92,25272,141 127.9%   
Net working cap to sales %40.230.7 130.9%  
Current ratio x1.71.7 95.7%  
Inventory Days Days8273 112.3%  
Debtors Days Days129105 123.4%  
Net fixed assets Rs m89,08283,854 106.2%   
Share capital Rs m906831 109.0%   
"Free" reserves Rs m124,461155,157 80.2%   
Net worth Rs m125,367155,988 80.4%   
Long term debt Rs m17,9331,304 1,375.2%   
Total assets Rs m249,839232,253 107.6%  
Interest coverage x5.519.6 28.1%   
Debt to equity ratio x0.10 1,711.1%  
Sales to assets ratio x0.60.8 81.6%   
Return on assets %0.49.1 4.1%  
Return on equity %-2.113.0 -16.5%  
Return on capital %8.712.6 69.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45084,193 61.1%   
Fx outflow Rs m19,47039,616 49.1%   
Net fx Rs m31,98044,577 71.7%   
CASH FLOW
From Operations Rs m14,68829,841 49.2%  
From Investments Rs m11,070-4,923 -224.9%  
From Financial Activity Rs m-8,906-25,159 35.4%  
Net Cashflow Rs m16,853-266 -6,335.5%  

Share Holding

Indian Promoters % 46.6 25.5 182.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 31.9 35.3 90.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.1 15.3 66.0%  
Shareholders   98,259 75,885 129.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  SUVEN LIFE SCIENCES  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jan 22, 2021 (Close)

TRACK LUPIN

LUPIN - SUN PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS